CYP19A1 and breast cancer: As the single predictive factor identified in BC and the indicator of endocrine therapy, the ER biomarker is most powerful in treatments with approximately 50% effective response to anti-estrogen or aromatase inhibitors for the ER-positive (ER+) phenotype, which comprises up to 70–80% of BC subtypes [3].